VILLEJUIF, France--(BUSINESS WIRE)--The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine proudly announces that six new organizations were approved as WIN Consortium members during the Consortium’s 2014 WIN Symposium, held June 23-24 in Paris, France. Joining the Consortium are: Asan Medical Center (Korea), Cambridge Cancer Center (UK), Cancer Research UK (UK), CEO Roundtable on Cancer (USA), Jefferson Kimmel Cancer Center (USA), and Memorial Sloan Kettering Cancer Center (USA).
The WIN Consortium is a global collaboration of leading healthcare organizations that have joined together around the shared mission of achieving the rapid translation of personalized cancer medicine discoveries into standards for clinical care for patients around the world.
“We are thrilled that these organizations are joining WIN,” said Dr. John Mendelsohn, Chairman of the WIN Consortium. “They bring immense capabilities and expertise that will be invaluable in building our shared capacity to impact the lives of cancer patients around the world through advancing personalized cancer medicine.”
Representing sixteen countries and four continents, WIN members now include 39 leading organizations from the academic, industry, and the non-profit sectors, who share information and collaboratively conduct multi-institutional, global clinical trials and scientific projects that aim to discover and validate significant advances in genomic and biomarker-driven cancer medicine.
Prof. Carlos Caldas, Professor of Cancer Medicine and Senior Group Leader at the Cancer Research UK Cambridge Institute said, 'The Cambridge Cancer Centre and the University of Cambridge are committed to applying our scientific and clinical expertise through innovative and global partnerships to prevent and alleviate the suffering of patients with cancer. The WIN Consortium represents a unique combination of scientific and clinical skills from all elements of the healthcare environment and we look forward to participating in furthering the testing and implementation of individualized approaches to cancer treatment”
Dr. Paul Sabbatini, Deputy Physician-in-Chief for Clinical Research at Memorial Sloan Kettering Cancer Center, stated: “We are delighted for Memorial Sloan Kettering Cancer Center to become a member of the WIN group. We look forward to working closely with our colleagues and believe that we have the greatest potential to accelerate the discovery of effective treatments for patients by combining our intellectual and scientific resources”.
Prof. Chang Sik Yu, Director of Asan Cancer Centre, noted that Asan Cancer Centre shares WIN’s mission, vision, and values for improving the lives of cancer patients. “Membership to WIN will provide us with the opportunity to promote ground-breaking, global clinical trials with other leading organizations to advance personalized cancer medicine. With this opportunity, we hope to make an important contribution to this worldwide effort to overcome cancer”.
Dr. Ian Walker, Cancer Research UK’s director of stratified medicine,
said: “Personalizing cancer treatments, by matching patients with the
therapies that will work best for them, could transform the lives of
people with the disease. Last year, Cancer Research UK spent over £40
million on research and infrastructure that will help deliver
personalized medicine for cancer patients.
“We’re excited to be part of the global initiative of translating our research into more targeted treatments. By collaborating on innovative projects we can accelerate progress and bring forward the day when all cancers are cured.”
Founded in 2010 with leadership from the University of Texas MD Anderson Cancer Center (USA) and the Institut Gustave Roussy (France), the WIN Consortium is a non-profit, non-governmental organization headquartered in Paris. WIN welcomes membership inquiries from organizations whose capabilities and mission align with those of the Consortium.